Atellica Ch 930 Analyzer
Payments companies reported to CMS as associated with Atellica Ch 930 Analyzer. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Atellica Ch 930 Analyzer, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Atellica Ch 930 Analyzer
These are the largest totals companies reported as associated with Atellica Ch 930 Analyzer. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Brian Poirier | Scottsdale, AZ | Clinical Pathology/Laboratory Medicine | $11,031.30 |
| Lori Daniels | San Diego, CA | Cardiovascular Disease | $10,117.90 |
| Renee Sullivan | Columbia, MO | Cardiovascular Disease | $9,284.00 |
| Hoda Hagrass | Little Rock, AR | Clinical Pathology/Laboratory Medicine | $1,775.73 |
| John Ward | Decatur, GA | Internal Medicine | $1,575.00 |
| Brian Rubin | Cleveland, OH | Anatomic Pathology | $1,425.39 |
| David Bosler | Rochester, MN | Anatomic Pathology & Clinical Pathology | $1,325.89 |
| Hooman Rashidi | Cleveland, OH | Hematology (Pathology) | $1,213.39 |
| Jose Jara Aguirre | Rochester, MN | Clinical Pathology | $1,032.98 |
| Yunchuan Mo | Washington, DC | Blood Banking & Transfusion Medicine | $907.72 |
Prescribed Atellica Ch 930 Analyzer?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.